SignateraLandmark CIRCULATE-Japan Study Shows Natera’s Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, announced new data recently presented on the clinical utility of Signatera, its personalized and tumor-informed molecular residual disease (MRD) test, at the American Society of Clinical Oncology’s 2022 Gastrointestinal Cancers Symposium (ASCO GI). The oral presentation included an updated analysis from the landmark...
